| Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan K Furuuchi, K Morimoto, T Yoshiyama, Y Tanaka, K Fujiwara, M Okumura, ... Respiratory medicine 152, 74-80, 2019 | 63 | 2019 |
| Potential cross-transmission of Mycobacterium abscessus among non-cystic fibrosis patients at a tertiary hospital in Japan K Fujiwara, M Yoshida, Y Murase, A Aono, K Furuuchi, Y Tanaka, K Ohta, ... Microbiology Spectrum 10 (3), e00097-22, 2022 | 12 | 2022 |
| Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease K Fujiwara, K Furuuchi, A Aono, F Uesugi, T Shirai, K Nakamoto, ... European Journal of Clinical Microbiology & Infectious Diseases 40, 247-254, 2021 | 12 | 2021 |
| Treatment duration and disease recurrence following the successful treatment of patients with Mycobacterium avium complex lung disease K Furuuchi, K Morimoto, A Kurashima, K Fujiwara, K Nakamoto, Y Tanaka, ... Chest 157 (6), 1442-1445, 2020 | 12 | 2020 |
| Health-related quality of life associates with clinical parameters in patients with NTM pulmonary disease K Kawahara, M Tabusadani, K Yamane, S Takao, Y Kuroyama, ... The International Journal of Tuberculosis and Lung Disease 25 (4), 299-304, 2021 | 11 | 2021 |
| Posttreatment Lymphopenia Is Associated With an Increased Risk of Redeveloping Nontuberculous Lung Disease in Patients With Mycobacterium avium Complex … K Furuuchi, K Fujiwara, F Uesgi, M Shimoda, S Seto, Y Tanaka, ... Clinical Infectious Diseases 73 (1), e152-e157, 2021 | 10 | 2021 |
| Molecular epidemiological characteristics of Mycobacterium abscessus complex derived from non-cystic fibrosis patients in Japan and Taiwan M Yoshida, JY Chien, K Morimoto, T Kinjo, A Aono, Y Murase, K Fujiwara, ... Microbiology spectrum 10 (3), e00571-22, 2022 | 9 | 2022 |
| Minimum inhibitory concentrations before and after antibacterial treatment in patients with Mycobacterium abscessus pulmonary disease K Fujiwara, F Uesugi, K Furuuchi, Y Tanaka, T Yoshiyama, M Saotome, ... Microbiology Spectrum 9 (3), e01928-21, 2021 | 9 | 2021 |
| Clinical features and prognosis of nontuberculous mycobacterial pleuritis: a multicenter retrospective study K Yagi, A Ito, K Fujiwara, E Morino, I Hase, Y Nakano, T Asakura, ... Annals of the American Thoracic Society 18 (9), 1490-1497, 2021 | 8 | 2021 |
| Clinical significance of anti-glycopeptidolipid-core IgA antibodies in patients newly diagnosed with Mycobacterium avium complex lung disease S Matsuda, T Asakura, K Morimoto, S Suzuki, K Fujiwara, K Furuuchi, ... Respiratory Medicine 171, 106086, 2020 | 7 | 2020 |
| The concavity of the maximal expiratory flow–volume curve reflects the extent of emphysema in obstructive lung diseases F Mochizuki, H Iijima, A Watanabe, N Tanabe, S Sato, M Shiigai, ... Scientific reports 9 (1), 13159, 2019 | 7 | 2019 |
| 症例 原疾患の治療が Trousseau 症候群に奏効した肺腺癌の 2 例 藤田純一， 蔵本健矢， 嶋田貴文， 藤原啓司， 望月芙美， 石川博一 日本呼吸器学会誌= Annals of the Japanese Respiratory Society/日本呼吸器学会 …, 2017 | 7 | 2017 |
| Analysis of risk factors for the development of a post-bronchoscopy respiratory infection in lung cancer patients M Shimoda, K Yamana, R Yano, M Saitou, K Fujiwara, K Furuuchi, ... Journal of Infection and Chemotherapy 27 (2), 237-242, 2021 | 6 | 2021 |
| Impact of Aspergillus precipitating antibody test results on clinical outcomes of patients with Mycobacterium avium complex lung disease T Shirai, K Furuuchi, K Fujiwara, K Nakamoto, Y Tanaka, H Ishii, ... Respiratory Medicine 166, 105955, 2020 | 6 | 2020 |
| Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: an observational study M Shimoda, T Yoshiyama, M Okumura, Y Tanaka, K Morimoto, H Kokutou, ... Medicine 101 (19), e29297, 2022 | 5 | 2022 |
| Mycobacterium avium complex pleuritis with elevated anti-glycopeptidolipid-core IgA antibody levels in pleural effusion K Furuuchi, K Morimoto, K Fujiwara, Y Tanaka, T Takemura, A Kurashima, ... Internal Medicine 58 (17), 2577-2579, 2019 | 5 | 2019 |
| Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a … F Watanabe, S Kaburaki, K Furuuchi, F Uesugi, K Fujiwara, Y Tanaka, ... Infection 50 (4), 879-887, 2022 | 4 | 2022 |
| Pharmacokinetics and adverse effects of clofazimine in the treatment of pulmonary non-tuberculous mycobacterial infection F Watanabe, K Furuuchi, K Hanada, K Fujiwara, F Uesugi, M Hiramatsu, ... Antimicrobial Agents and Chemotherapy 66 (8), e00441-22, 2022 | 3 | 2022 |
| Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease Y Matsumura, M Tabusadani, K Yamane, S Takao, Y Kuroyama, K Mori, ... The International Journal of Tuberculosis and Lung Disease 26 (4), 310-316, 2022 | 3 | 2022 |
| Influence of chronic sputum symptoms on quality of life in patients with nontuberculous mycobacterial pulmonary disease: a cross-sectional study K Yamane, K Furuuchi, M Tabusadani, S Takao, Y Kuroyama, ... Respiratory Investigation 60 (2), 277-283, 2022 | 3 | 2022 |
Kozo MorimotoFukujuji Hospital, Japan Anti-Tuberculosis AssociationVerified email at ybb.ne.jp
